Pre-clinical targeting of enzalutamide-resistant prostate cancer
Prostate cancer causes morbidity and mortality for thousands of Canadian men each year. Castration remains the primary treatment for recurrent or metastatic prostate cancer. However, castration is never curative, and the cancer inevitably recurs as castration resistant prostate cancer (CRPC). Newer...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2017
|
| Online Access: | http://hdl.handle.net/2429/60230 |